Skin cancer prevention and risk reduction | 53 min
88
students
0
Free
In this highly practical and engaging webinar from the MIA Nurse Webinar Series, MIA Dermatologist Dr Niamh-Anna O’Sullivan busts myths and controversies around sun...
Free
Critical questions for a melanoma pathologist | 36 min
97
students
0
Free
The role of pathologist in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the...
Free
Advances in skin cancer management | 21 min
198
students
0
Free
This presentation was recorded at the 2022 Australasian Skin Cancer Congress, organised by the Skin Cancer College Australasia. In this presentation, Surgeon A/Prof Sydney...
Free
Current management of advanced non-melanoma skin cancer | 32 min
201
students
0
Free
This presentation was recorded at the 2022 Australasian Skin Cancer Congress, organised by the Skin Cancer College Australasia. In this presentation, Medical Oncologist Dr...
Free
Toxicity management in melanoma | 45 min
307
students
0
Free
Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of...
Free
Updates in skin cancer diagnosis and management | RACGP ACCREDITED | 2 hrs
403
students
0
Free
In the rapidly evolving field of skin cancer medicine, it is important for GPs to be up to date with the latest developments to...
Free
Update on the adjuvant treatment of melanoma in 2021 | 13 min
505
students
0
Free
In this presentation, A/Prof Andrew Haydon reviews the efficacy data from 6 large-scale Phase III studies that are looking at the use of modern...
Free
Staging melanoma and bulky palpable Stage III melanoma – is surgery necessary? | 10 min
505
students
0
Free
In this presentation, A/Prof Sydney Ch’ng discovers the current recommendations for sentinel node biopsy and the implications of high-risk Stage II melanoma trial findings....
Free
Management of in-transit melanoma in the time of active systemic therapy | 11 min
505
students
0
Free
With up to 14% of patients developing in-transit disease and biologically diverse pathobiological behaviour is observed, in-transit disease is a significant clinical burden. In...
Free